Abstract
Nitric oxide (NO) deficiency has been implicated in many pathological and physiological processes within the mammalian body providing a plausible biologic basis for the use of NO replacement therapy in these conditions. Exogenous NO sources may hopefully constitute a powerful way to supplement NO when the body cannot generate enough for normal biological functions. This theory has opened up the possibility of designing new drugs that are capable of delivering NO into tissues and the bloodstream in a sustained and controlled manner. This objective has been reached by grafting an organic nitrate structure onto existing molecules with various spacers such as aliphatic or aromatic chain, with different degree of complexity. This approach has led to the synthesis of several new chemical entities in various pharmacological classes, whose profile seems to challenge the parent drug not only on the basis of new pharmacological properties but also on a better toxicological and safety profile. In this article, general aspects on NO and NO donors are reviewed. Major focus is placed upon recent developments of novel NO donors, NO releasing device(s) as well as innovative improvements to conventional NO donors. Several examples are given in some important therapeutic indications such as cardiovascular diseases (NO-aspirin), pain and inflammation (NO-paracetamol), osteoporosis and urinary incontinence (NO flurbiprofen with aliphatic spacer), Alzheimers disease (NO-flurbiprofen with anti-oxidant spacer), respiratory disorders (NO-steroids).
Keywords: Nitric-Oxide Releasing Molecules, iNOs (inducible NO synthase), Rationale, Bronchodilation, NO-flurbiprofen
Current Pharmaceutical Design
Title: Nitric-Oxide Releasing Molecules : A New Class of Drugs with Several Major Indications
Volume: 8 Issue: 3
Author(s): J. L. Burgaud, J. P. Riffaud and P. Del Soldato
Affiliation:
Keywords: Nitric-Oxide Releasing Molecules, iNOs (inducible NO synthase), Rationale, Bronchodilation, NO-flurbiprofen
Abstract: Nitric oxide (NO) deficiency has been implicated in many pathological and physiological processes within the mammalian body providing a plausible biologic basis for the use of NO replacement therapy in these conditions. Exogenous NO sources may hopefully constitute a powerful way to supplement NO when the body cannot generate enough for normal biological functions. This theory has opened up the possibility of designing new drugs that are capable of delivering NO into tissues and the bloodstream in a sustained and controlled manner. This objective has been reached by grafting an organic nitrate structure onto existing molecules with various spacers such as aliphatic or aromatic chain, with different degree of complexity. This approach has led to the synthesis of several new chemical entities in various pharmacological classes, whose profile seems to challenge the parent drug not only on the basis of new pharmacological properties but also on a better toxicological and safety profile. In this article, general aspects on NO and NO donors are reviewed. Major focus is placed upon recent developments of novel NO donors, NO releasing device(s) as well as innovative improvements to conventional NO donors. Several examples are given in some important therapeutic indications such as cardiovascular diseases (NO-aspirin), pain and inflammation (NO-paracetamol), osteoporosis and urinary incontinence (NO flurbiprofen with aliphatic spacer), Alzheimers disease (NO-flurbiprofen with anti-oxidant spacer), respiratory disorders (NO-steroids).
Export Options
About this article
Cite this article as:
Burgaud L. J., Riffaud P. J. and Soldato Del P., Nitric-Oxide Releasing Molecules : A New Class of Drugs with Several Major Indications, Current Pharmaceutical Design 2002; 8 (3) . https://dx.doi.org/10.2174/1381612023396357
DOI https://dx.doi.org/10.2174/1381612023396357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glaucoma and Alzheimer Disease: One Age-Related Neurodegenerative Disease of the Brain
Current Neuropharmacology Non-invasive Cerebellar Stimulation in Cerebellar Disorders
CNS & Neurological Disorders - Drug Targets MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Current Genomics Efficacy of Duloxetine in Patients with Chronic Pain Conditions
Current Drug Therapy Contributions of Functional Neuroimaging to Clinical and Cognitive Neuropsychology: A Selective Review
Current Medical Imaging Dutasteride in Androgenetic Alopecia: An Update
Current Clinical Pharmacology Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far
Current Alzheimer Research PPAR-γ: Therapeutic Prospects in Parkinson's Disease
Current Drug Targets Pathogenesis of Type 1 Diabetes: Regulation of Adhesion Molecules and Immune Cell Trafficking
Current Immunology Reviews (Discontinued) Microcapsules of Cajá-manga (Spondias dulcis Parkinson): Influence of Different Types of Encapsulating Agents and Drying Technology
Current Nutrition & Food Science Mitochondrial Genomics and Proteomics
Current Genomics Meet Our Editorial Board Member
Current Alzheimer Research Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology Clinical Application of Ghrelin
Current Pharmaceutical Design Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Direct Targets and Subsequent Pathways for Molecular Hydrogen to Exert Multiple Functions: Focusing on Interventions in Radical Reactions
Current Pharmaceutical Design The Assessment of Some Metabolic Markers by Combination of Ursolic Acid Supplementation and Resistance Training in Young Older Obese Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms of Neuropathic Pain
Current Medicinal Chemistry - Central Nervous System Agents Pharmacological Targeting of the Hsp70 Chaperone
Current Topics in Medicinal Chemistry Episodic Memory Dysfunction in Individuals at High-Risk of Psychosis: A Systematic Review of Neuropsychological and Neurofunctional Studies
Current Pharmaceutical Design